BR9711763A - Prote¡na semelhante a tnf-beta para tratamento do cÆncer de prÄstata e mol-cula de acido nucleico composi-oes farmaceutica e processos correlatos - Google Patents

Prote¡na semelhante a tnf-beta para tratamento do cÆncer de prÄstata e mol-cula de acido nucleico composi-oes farmaceutica e processos correlatos

Info

Publication number
BR9711763A
BR9711763A BR9711763A BR9711763A BR9711763A BR 9711763 A BR9711763 A BR 9711763A BR 9711763 A BR9711763 A BR 9711763A BR 9711763 A BR9711763 A BR 9711763A BR 9711763 A BR9711763 A BR 9711763A
Authority
BR
Brazil
Prior art keywords
tnf
beta
protein
treatment
nucleic acid
Prior art date
Application number
BR9711763A
Other languages
English (en)
Inventor
Mark G Erlander
Shaoming Huang
Michael A Jackson
Per A Peterson
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of BR9711763A publication Critical patent/BR9711763A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9711763A 1996-09-11 1997-09-11 Prote¡na semelhante a tnf-beta para tratamento do cÆncer de prÄstata e mol-cula de acido nucleico composi-oes farmaceutica e processos correlatos BR9711763A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2592396P 1996-09-11 1996-09-11
PCT/US1997/016191 WO1998011224A1 (en) 1996-09-11 1997-09-11 Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods

Publications (1)

Publication Number Publication Date
BR9711763A true BR9711763A (pt) 1999-08-24

Family

ID=21828810

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711763A BR9711763A (pt) 1996-09-11 1997-09-11 Prote¡na semelhante a tnf-beta para tratamento do cÆncer de prÄstata e mol-cula de acido nucleico composi-oes farmaceutica e processos correlatos

Country Status (12)

Country Link
US (1) US6107476A (pt)
EP (1) EP0950105A1 (pt)
JP (1) JP2001500732A (pt)
KR (1) KR20000038040A (pt)
CN (1) CN1233289A (pt)
AU (1) AU735776B2 (pt)
BR (1) BR9711763A (pt)
CA (1) CA2265444C (pt)
IL (2) IL128872A0 (pt)
NO (1) NO324815B1 (pt)
NZ (1) NZ334592A (pt)
WO (1) WO1998011224A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US6524802B1 (en) * 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
US6465181B2 (en) * 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
DE60032355T2 (de) * 1999-05-17 2007-04-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh NEUROPROTEKTIVE EIGENSCHAFTEN VON GDF-15, EINEM VERTRETER DER TGF-ß-SUPERFAMILIE
AU2001288770A1 (en) * 2000-09-08 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US20070237713A1 (en) * 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
US9828415B2 (en) 2013-01-30 2017-11-28 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3174894B1 (en) 2014-07-30 2021-06-23 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CA3016035A1 (en) 2016-03-31 2017-10-05 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
JPH07250688A (ja) * 1994-01-28 1995-10-03 Sagami Chem Res Center ＴＧＦ−βスーパーファミリー蛋白質をコードするヒト新規ｃＤＮＡ
JPH07258293A (ja) * 1994-03-23 1995-10-09 Asahi Chem Ind Co Ltd 新規な蛋白質ならびにその製造方法
WO1996018730A1 (en) * 1994-12-15 1996-06-20 Human Genome Sciences, Inc. Prostatic growth factor
AU711368B2 (en) * 1995-06-22 1999-10-14 St Vincent's Hospital Sydney Limited Novel TGF-beta like cytokine
EP0833912B1 (en) * 1995-06-22 2009-02-25 St Vincent's Hospital Sydney Limited Novel tgf-beta like cytokine
US6524802B1 (en) * 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14

Also Published As

Publication number Publication date
EP0950105A1 (en) 1999-10-20
CA2265444C (en) 2008-11-18
IL128872A (en) 2009-08-03
IL128872A0 (en) 2000-01-31
KR20000038040A (ko) 2000-07-05
AU735776B2 (en) 2001-07-12
CN1233289A (zh) 1999-10-27
NO324815B1 (no) 2007-12-10
WO1998011224A1 (en) 1998-03-19
JP2001500732A (ja) 2001-01-23
AU4344297A (en) 1998-04-02
CA2265444A1 (en) 1998-03-19
NO991161L (no) 1999-05-07
NO991161D0 (no) 1999-03-10
NZ334592A (en) 2000-10-27
US6107476A (en) 2000-08-22

Similar Documents

Publication Publication Date Title
BR9711763A (pt) Prote¡na semelhante a tnf-beta para tratamento do cÆncer de prÄstata e mol-cula de acido nucleico composi-oes farmaceutica e processos correlatos
ID27199A (id) Penghambat transferase protein farnesil untuk pengobatan artropatis
BR9809112B1 (pt) processo para preparação de clopidogrel.
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
EE04781B1 (et) 2-fenüülasendatud imidasotriasinoonid kui fosfodiesteraasi inhibiitorid ja nende valmistamismeetod
DE59912604D1 (de) Verfahren zur isolierung und aufreinigung von nucleinsäuren
DE69918879D1 (de) Verfahren zur Mikroverkapselung von festem Produkt
PT832567E (pt) Processo para o fabrico de chocolate ou produto analogo contendo agua
BR9408407A (pt) Uso de inibidores pla2 como tratamento para doença de alzheimer
IT1286178B1 (it) Sistema per la localizzazione di veicoli o oggetti mobili
DE69822473D1 (de) Lipid-polyamid-konjugate und zusammensetzungen zur verabreichung von nucleinsäuremolekülen
BR9711296A (pt) Composto processo terap-utico para inibir o crescimento de c-lulas de c ncer e composi-Æo farmac-utica
EP1007706A4 (en) RNA-BINDING PROTEIN AND BINDING POINT USEFUL FOR THE EXPRESSION OF RECOMBINANT MOLECULES
ID22383A (id) Metode untuk identifikasi tempat-tempat tempelan genetika yang tergabung dengan tempat sifat
DE69819124D1 (de) Lyophilisation von kultivierten, menschlichen zellen zur konservierung der rna und dna
PT917879E (pt) Processo melhorado para estabilizacao de proteinas
NO986177D0 (no) FremgangsmÕte for fremstilling av terapeutisk DNA
BR9703737A (pt) Processo para preparar preparados pouco salinos de produtos de condensação
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
BR9806083A (pt) Composi-Æo farmac-utica para o tratamento da hapattite c
BR9706942A (pt) Método de transformação genética de árvores
DE69816988D1 (de) Verfahren und zusammemsetzungen zur förderung der biologischen effektivität exogener chemische substanzen in plflanzen
PT1131299E (pt) Processo para o fabrico de 5-hidroxipirazois ou de 3-hidroxipirazois 1-substituidos
DE69841910D1 (de) Verfahren zur Isomerisierung von halogenierten Aromaten
PT915655E (pt) Processo e composicao para o tratamento antiparasitico do ambiente circundante de animais

Legal Events

Date Code Title Description
TE Change of address
PC Transfer

Free format text: JOHNSON & JOHNSON (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1818 DE 08/11/2005 POR TER SIDO APRESENTADA PAPELETA DE ESCLARECIMENTO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE C12N 15/16 C07K 14/495

Ipc: C07K 14/495 (2007.01), C12N 15/12 (2007.01), A61K

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA (ART. 8O COMBINADO COM ART. 13 DA LPI), NAO APRESENTA SUFICIENCIA DESCRITIVA (ART. 24 DA LPI) E AS REIVINDICACOES ESTAO INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO (ART. 25 DA LPI).